Display Settings:

Format

Send to:

Choose Destination

    Chem Biol. 2005 Jul;12(7):847-55.

    Ligand-regulated peptides: a general approach for modulating protein-peptide interactions with small molecules.

    Binkowski BF, Miller RA, Belshaw PJ.

    Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.

    We engineered a novel ligand-regulated peptide (LiRP) system where the binding activity of intracellular peptides is controlled by a cell-permeable small molecule. In the absence of ligand, peptides expressed as fusions in an FKBP-peptide-FRB-GST LiRP scaffold protein are free to interact with target proteins. In the presence of the ligand rapamycin, or the nonimmunosuppressive rapamycin derivative AP23102, the scaffold protein undergoes a conformational change that prevents the interaction of the peptide with the target protein. The modular design of the scaffold enables the creation of LiRPs through rational design or selection from combinatorial peptide libraries. Using these methods, we identified LiRPs that interact with three independent targets: retinoblastoma protein, c-Src, and the AMP-activated protein kinase. The LiRP system should provide a general method to temporally and spatially regulate protein function in cells and organisms.

    PMID: 16039531 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Tacrolimus (Prograf®)

      Tacrolimus is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ) in people who have received kidney, liver, or heart transplants. ...